AstraZeneca: New Data Presented at ATS 2024 Show the Potential of Tezspire to Play a Role in the Future Treatment of Chronic Obstructive Pulmonary Disease
May 21, 2024
May 21, 2024
WILMINGTON, Delaware, May 21 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen's TEZSPIRE(R) (tezepelumab) led to a 1 . . .
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen's TEZSPIRE(R) (tezepelumab) led to a 1 . . .